Ocrevus Zunovo with Halozyme's Enhanze drug delivery technology is used for the treatment of relapsing multiple sclerosis and ...
Fintel on MSN3d
JP Morgan Downgrades Halozyme Therapeutics (HALO)Fintel reports that on September 19, 2024, JP Morgan downgraded their outlook for Halozyme Therapeutics (NasdaqGS:HALO) from ...
Halozyme Therapeutics (HALO) stock drops after J.P. Morgan downgrade, but analyst raises price target on Enhanze drug ...
Halozyme Therapeutics, Inc. (HALO) Stock Settles at $61.93: What’s Contributing to This Price Point?
Halozyme Therapeutics, Inc. (HALO) stock saw a decline, ending the day at $61.93 which represents a decrease of $-0.98 or -1.56% from the prior close of $62.91. The stock opened at $62.91 and touched ...
Kaskela Law LLC announces that it is investigating Halozyme Therapeutics, Inc. ("Halozyme") on behalf of the company's shareholders. The investigation seeks to determine whether Halozyme and/or the ...
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and ...
Astute Analytica has released a comprehensive report on the Global Hyaluronidase Market, providing an in-depth analysis of its current and future landscape. This market research document identifies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback